---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-227407"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:14:39.042932+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA approves KarXT (Cobenfy) for schizophrenia; triggers $25M milestone for Royalty Pharma from PureTech deal

## Summary
- FDA approved KarXT (xanomeline-trospium) for adult schizophrenia; BMS to market as Cobenfy.
- Royalty Pharma's March 2023 PureTech deal: $100M upfront, up to $400M milestones, 3% royalty on sales up to $2B (then 1%).
- Approval triggers $25M milestone payment from Royalty Pharma to PureTech.
- Approval validates Royalty Pharma's investment and unlocks potential future royalty revenue.

## SEC filing metadata
- accession: 0001193125-24-227407
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312524227407/0001193125-24-227407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312524227407/d889954d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-227407
- JSON: https://secwatch.observer/filing/0001193125-24-227407.json
- Plain text: https://secwatch.observer/filing/0001193125-24-227407.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.